{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T19:24:13Z","timestamp":1765826653543},"reference-count":36,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2008,7,7]],"date-time":"2008-07-07T00:00:00Z","timestamp":1215388800000},"content-version":"vor","delay-in-days":2728,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2001,1,17]]},"abstract":"<jats:sec><jats:title>Background:<\/jats:title><jats:p>Short\u2010term proton pump inhibitor\u2010based triple therapies for the eradication of <jats:italic>Helicobacter pylori<\/jats:italic> are used widely. The eradication rates vary greatly from country to country and from region to region.<\/jats:p><\/jats:sec><jats:sec><jats:title>Aim:<\/jats:title><jats:p>To assess the efficacy at eradicating <jats:italic>H. pylori<\/jats:italic> of 1\u2010week regimens containing three medications: omeprazole (O) or colloidal bismuth subcitrate (B), furazolidone (F) or metronidazole (M), and amoxicillin (A) or clarithromycin (C).<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods:<\/jats:title><jats:p>A multicentre study involving 20 hospitals in different regions of China. A total of 892 patients with <jats:italic>H. pylori\u2010<\/jats:italic>positive non\u2010ulcer dyspepsia or healed duodenal ulcer confirmed by endoscopy were recruited to receive, randomly, one of four regimens: OMC, OFC, OFA, and BFC, b.d. for 7\u2003days. <jats:sup>13<\/jats:sup>C\u2010urea breath test was performed 4\u20138\u2003weeks after completion of treatment.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results:<\/jats:title><jats:p>The eradication rates with per protocol\/intention\u2010to\u2010treat analyses were: OMC (<jats:italic>n<\/jats:italic>=217\/219) 66%\/65%; OFC (<jats:italic>n<\/jats:italic>=227\/229) 69%\/69%; OFA (<jats:italic>n<\/jats:italic>=223\/225) 87%\/86%; and BFC (<jats:italic>n<\/jats:italic>=214\/219) 80%\/78%. The eradication rate (per protocol analysis) in duodenal ulcer (79%) was higher than that in non\u2010ulcer dyspepsia (73%, <jats:italic>P<\/jats:italic>=0.033). Patient compliance was good. The adverse events of the four regimens were mild, and mainly gastrointestinal.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusions:<\/jats:title><jats:p>The omeprazole, furazolidine and amoxicillin regimen achieves a high <jats:italic>H. pylori<\/jats:italic> eradication rate in different geographical regions of China.<\/jats:p><\/jats:sec>","DOI":"10.1046\/j.1365-2036.2001.00895.x","type":"journal-article","created":{"date-parts":[[2003,3,11]],"date-time":"2003-03-11T03:43:00Z","timestamp":1047354180000},"page":"81-86","source":"Crossref","is-referenced-by-count":32,"title":["A multicentre study on eradication of <i>Helicobacter pylori<\/i> using four 1\u2010week triple therapies in China"],"prefix":"10.1111","volume":"15","author":[{"name":"CHINESE NATIONAL COOPERATIVE STUDY GROUP FOR HELICOBACTER PYLORI","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.\u2010D.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"W.\u2010Z.","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.\u2010J.","family":"Hu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Q.","family":"Ouyang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.\u2010L.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.\u2010Y.","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"N.\u2010N.","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2008,7,7]]},"reference":[{"key":"e_1_2_6_2_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.41.1.8"},{"key":"e_1_2_6_3_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1998.tb00537.x"},{"key":"e_1_2_6_4_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00009.x"},{"key":"e_1_2_6_5_2","first-page":"71","article-title":"Characterization of clinical isolates of Helicobacter pylori in Singapore","volume":"94","author":"Hua J","year":"1998","journal-title":"Microbios"},{"key":"e_1_2_6_6_2","first-page":"A 238","article-title":"Metronidazole resistance is high in Korea and Colombia and appears to be rapidly increasing in the US","volume":"110","author":"Reddy R","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_7_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.455_t.x"},{"key":"e_1_2_6_8_2","first-page":"576","article-title":"The changing trend of metronidazole and clarithromycin resistance rates","volume":"39","author":"Shi T","year":"2000","journal-title":"Chin J Intern Med"},{"key":"e_1_2_6_9_2","first-page":"503","article-title":"The efficacy of furazolidone and metronidazole in the treatment of chronic gastritis associated with Helicobacter (Campylobacter) pylori\u2014a randomized double\u2010blind placebo\u2010controlled clinical trial","volume":"37","author":"Xiao SD","year":"1990","journal-title":"Hepatogastroenterology"},{"key":"e_1_2_6_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00487.x"},{"key":"e_1_2_6_11_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00492.x"},{"key":"e_1_2_6_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1523-5378.1996.tb00027.x"},{"key":"e_1_2_6_13_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0016-5085(99)70119-8"},{"key":"e_1_2_6_14_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00230.x"},{"key":"e_1_2_6_15_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.1998.00602.x"},{"key":"e_1_2_6_16_2","first-page":"263","article-title":"Reliability of 13C\u2010urea breath test for detection of Helicobacter pylori infection","volume":"18","author":"Wu SM","year":"1998","journal-title":"Chinese J Digestion"},{"key":"e_1_2_6_17_2","first-page":"1048","article-title":"Double\u2010blind short\u2010term trial of furazolidone in peptic ulcer","volume":"1","author":"Zheng ZT","year":"1985","journal-title":"Lancet"},{"key":"e_1_2_6_18_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-1746.1992.tb01034.x"},{"key":"e_1_2_6_19_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00166.x"},{"key":"e_1_2_6_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00172.x"},{"key":"e_1_2_6_21_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00653.x"},{"key":"e_1_2_6_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00640.x"},{"key":"e_1_2_6_23_2","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.34.9.1637"},{"key":"e_1_2_6_24_2","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/43.1.47"},{"key":"e_1_2_6_25_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199409000-00004"},{"key":"e_1_2_6_26_2","first-page":"1","article-title":"One\u2010week low\u2010dose triple therapy: new standards for Helicobacter pylori treatment","volume":"7","author":"Goddard A","year":"1995","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_6_27_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.39.6.781"},{"key":"e_1_2_6_28_2","first-page":"A93","article-title":"Bazzoli\u2010like schemes are not optimal treatment for Helicobacter pylori eradication in Brussels, Belgium","volume":"110","author":"Deltenre M","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_29_2","first-page":"A170","article-title":"Randomised study comparing two seven days triple therapies with lansoprazoe and low dose of clarithromycin plus amoxicillin or tinidazole for Helicobacter pylori eradication","volume":"110","author":"Lamouliatte H","year":"1996","journal-title":"Gastroenterology"},{"key":"e_1_2_6_30_2","first-page":"A37","article-title":"Omeprazole once or twice daily with clarithromycin\u2003+\u2003metronidazole in H. pylori eradication: a cohort study","volume":"39","author":"Chiba N","year":"1996","journal-title":"Gut"},{"key":"e_1_2_6_31_2","first-page":"A84","article-title":"Duodenal ulcer and functional dyspepsia: different susceptibility of Helicobacter pylori to eradicating therapy","volume":"112","author":"Catalona F","year":"1997","journal-title":"Gastroenterology"},{"key":"e_1_2_6_32_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199908002-00005"},{"key":"e_1_2_6_33_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.46.3.321"},{"key":"e_1_2_6_34_2","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1128\/jcm.35.6.1344-1347.1997","article-title":"Equally high prevalences of infection with cagA\u2010positive Helicobacter pylori in Chinese patients with peptic ulcer disease and those with chronic gastritis\u2010associated dyspepsia","volume":"35","author":"Pan ZJ","year":"1997","journal-title":"J Clin Microbiol"},{"key":"e_1_2_6_35_2","doi-asserted-by":"publisher","DOI":"10.1086\/515601"},{"key":"e_1_2_6_36_2","first-page":"86","article-title":"Prevalence and genetic diversity of cagA 3\u2032region and vacA in Helicobacter pylori strains isolated from Shanghai population and their relations to gastoduodenal diseases","volume":"6","author":"Li XB","year":"2000","journal-title":"Chin J Gastroenterol"},{"key":"e_1_2_6_37_2","first-page":"90","article-title":"gene subtypes of Helicobacter pylori in Guangdong area and their relationships with gastrointestinal diseases","volume":"6","author":"He Y","year":"2000","journal-title":"Chin J Gastroenterol"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00895.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1046%2Fj.1365-2036.2001.00895.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1046\/j.1365-2036.2001.00895.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,16]],"date-time":"2023-10-16T22:46:33Z","timestamp":1697496393000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1046\/j.1365-2036.2001.00895.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2001,1,17]]},"references-count":36,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2001,1,17]]}},"alternative-id":["10.1046\/j.1365-2036.2001.00895.x"],"URL":"https:\/\/doi.org\/10.1046\/j.1365-2036.2001.00895.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"type":"print","value":"0269-2813"},{"type":"electronic","value":"1365-2036"}],"subject":[],"published":{"date-parts":[[2001,1,17]]}}}